Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Giulia Zorzi has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Gare au chaud lapin

    by L. Frisson, F. Aboubakar, G. Zorzi, V. Roelants, L. Pothen, L. Bamps, H. Yildiz, A. Benyamine

  • Open Access

    Evaluation of a Ten-Antigen Immunodot Test in Autoimmune Hepatitis and Primary Biliary Cholangitis: Lessons Learned for a Tertiary Care Academic Hospital

    by Giulia Zorzi, Perrin Ngougni Pokem, Geraldine Dahlqvist, Bénédicte Délire, Nicolas Lanthier, Peter Starkel, Yves Horsmans, Cedric Aupaix, Samia Jnaoui, Damien Gruson

    Autoimmune diseases of the liver and biliary tract require timely and accurate diagnosis. This study evaluates the D-tek panel (D-Tek, Mons, Belgium) of 10 immunodot antigens for its effectiveness in diagnosing autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC). We retrospectively analysed serum samples from 111 patients who had undergone routine testing, including indirect immunofluorescence (IIF) and enzyme-linked immunosorbent assays (ELISA), to confirm or exclude autoimmune liver or biliary tract disease. The panel tested for M2/nPDC, M2/OGDC-E2, M2/BCOADC-E2, M2/PDC-E2, gp210, sp100, LKM1, LC1, SLA, and F-actin antigens. Results showed that all positive IIF+ELISA results were confirmed by the immunodot panel, except for two samples from patients who had never been diagnosed with AIH. The immunodot test identified over 20 additional autoantibodies in samples initially negative by IIF, corroborated by laboratory imaging and medical history. The immunodot technique proved to be a quick, sensitive, and specific method with high overall accuracy. This study suggests that the immunodot technique may be an effective screening and confirmatory method for autoimmune liver diseases, potentially improving diagnostic efficiency and accuracy in clinical practice.

  • Open Access

    Evaluation of a Ten Immunodot Antigens Test in Autoimmune Hepatitis and Primary Biliary Cholangitis, Lessons Learned for a Tertiary Care Academic Hospital

    by Giulia Zorzi, Perrin Ngougni Pokem, Geraldine Dahlqvist, Bénédicte Délire, Nicolas Lanthier, Peter Starkel, Yves Horsmans, Cedric Aupaix, Samia Jnaoui, Damien Gruson

    Autoimmune diseases of the liver and biliary tract require timely and accurate diagnosis. This study evaluates the D-tek panel (D-Tek, Mons, Belgium) of 10 immunodot antigens for its effectiveness in diagnosing autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC). We retrospectively analysed serum samples from 111 patients who had undergone routine testing, including indirect immunofluorescence (IIF) and enzyme-linked immunosorbent assays (ELISA), to confirm or exclude autoimmune liver or biliary tract disease. The panel tested for M2/nPDC, M2/OGDC-E2, M2/BCOADC-E2, M2/PDC-E2, gp210, sp100, LKM1, LC1, SLA, and F-actin antigens. Results showed that all positive IIF+ELISA results were confirmed by the immunodot panel, except for two samples from patients never diagnosed with AIH. The immunodot test identified over 20 additional autoantibodies in samples initially negative by IIF, corroborated by laboratory imaging and medical history. The immunodot technique proved to be a quick, sensitive, and specific method with high overall accuracy. This study suggests that the immunodot technique may be an effective screening and confirmatory method for autoimmune liver diseases, potentially improving diagnostic efficiency and accuracy in clinical practice.

  • Open Access

    [18F]FDG-PET/CT in Idiopathic Inflammatory Myopathies: Retrospective Data from a Belgian Cohort

    by Halil Yildiz, Charlotte Lepere, Giulia Zorzi, Olivier Gheysens, Fabien Roodhans, Lucie Pothen

    [18F]FDG-PET/CT is a useful tool for diagnosis and cancer detection in idiopathic inflammatory myopathies (IIMs), especially polymyositis (PM) and dermatomyositis (DM). Data deriving from Europe are lacking. We describe [18F]FDG-PET/CT results in a Belgian cohort with IIMs, focusing on patients with PM and DM. All of the cases of IIMs admitted between December 2010 and January 2023 to the Cliniques Universitaires Saint-Luc (Belgium) were retrospectively reviewed. In total, 44 patients were identified with suspected IIMs; among them, 29 were retained for final analysis. The mean age of the retained patients was 48.7 years; 19 patients were female (65.5%). Twenty-two patients had DM and seven had PM. The mean serum creatinine kinase (CK) and the mean CRP levels were 3125 UI/L and 30.3 mg/L, respectively. [18F]FDG-PET/CT imaging was performed for 27 patients, detecting interstitial lung diseases (ILDs) in 7 patients (25.9%), cancer in 3 patients (11.1%), and abnormal muscle FDG uptake compatible with myositis in 13 patients (48.1%). All of the patients who were detected to have ILDs via PET/CT imaging were confirmed using a low-dose lung CT scan. Among the patients who were detected to have abnormal muscle FDG uptake via PET/CT scans (13/28), the EMG was positive in 12 patients (p = 0.004), while the MRI was positive in 8 patients (p = 0.02). We further observed that there was a significantly higher level of CK in the group with abnormal muscle FDG uptake (p = 0.008). Our study showed that PET/CT is useful for detecting cancer and ILDs. We showed that the detection of abnormal muscle uptake via PET/CT was in accordance with EMG and MRI results, as well as with the mean CK value, and that the presence of dyspnea was significantly associated with the presence of ILDs detected via PET/CT imaging (p = 0.002).


  • Open Access

    Retrospective analysis of a lactose breath test in a gastrointestinal symptomatic population of Northeast Italy: use of (H2+2CH4) versus H2 threshold

    by Gregorio Peron, Stefano Dall'ACqua, Vincenzo Sorrenti, Maria Carrara, Stefano Fortinguerra, Giulia Zorzi, Alessandro Buriani

    Background: Lactose malabsorption is normally evaluated by measuring exhaled H2 produced by intestinal flora, from unabsorbed lactose. However, differing microbiome composition can lead to the production of CH4 instead of H2; hence, some authors challenge the H2 method sensitivity and favor the evaluation of both intestinal gases. Aim: To compare different approaches to usage of a lactose breath test for lactose malabsorption diagnosis, after medical evaluation of gastrointestinal symptoms. Methods: In a retrospective observational study, we compared the 2 approaches in a population of 282 subjects in Northern Italy. Following oral lactose administration, exhaled samples were harvested every 30 minutes for 4 hours and prepared for H2 and CH4 analysis. Basal gas levels were subtracted from H2 and CH4 ppm and values at 4 hours and peaks were considered for analysis. Results: Applying the standard methodology, which takes separately into consideration H2 and CH4 produced in the intestinal lumen, the results indicated that 11.7% of the patients were diagnosed “positive” for hypolactasia, differently from what was expected. Conversely, taking into consideration the sum of H2 and CH4, the percentage increased to 62.8%, closer to the expected one. No significant differences were found when comparing the 2 groups for age, gender, or symptoms. The sizable difference between the 2 approaches is likely linked to gut microbiome variability, and consequently the different production of the 2 gases, in the population. Conclusion: The threshold normally used for lactose breath test should be reconsidered and changed, merging H2 and CH4 stoichiometric values to increase sensitivity.


    • 1 June 2017
      • Vol. 25  (2) , 133-141

    Prevalence of intestinal parasitoses detected in Padua teaching hospital, Italy, March 2011 - February 2013.

    by Andrea Bartolini, Giulia Zorzi, Valeria Besutti

    The aim of this study was to evaluate the distribution of parasitic intestinal infections in patients attending Padua teaching hospital during a two-year period. Between 1st March 2011 and 28th February 2013, we examined stool specimens from 7341 patients (6127 Italians, 1214 non-Italians) for ova and parasites using microscopy, rapid enzyme immunoassays, culture techniques and molecular methods. Stools of 1080 patients (14.71%) were positive for parasites; a total of 1349 intestinal parasites were counted. Protozoa were detected in 1028/1080 patients (95.19%), while helminths were present in 80/1080 patients (7.41%). The protozoa most commonly detected were Blastocystis spp., Dientamoeba fragilis and Giardia duodenalis. Enterobius vermicularis was the helminth most frequently encountered. Of the 1080 infected patients, 227 (21.02%) had more than one parasite in their stool. To conclude, in Italy intestinal parasitoses must be unquestionably considered in differential diagnoses of gastrointestinal diseases. For this purpose, sound knowledge of epidemiology is essential.


  • Open Access

    Reference Values for a Panel of Cytokinergic and Regulatory Lymphocyte Subpopulations

    by Vincenzo Sorrenti, Bruno Marenda, Stefano Fortinguerra, Claudia Cecchetto, Roberta Quartesan, Giulia Zorzi, Morena Zusso, Pietro Giusti, Alessandro Buriani

    Sorrenti V, et al. Immune Netw. 2016 Dec;16(6):344-357. https://doi.org/10.4110/in.2016.16.6.344


  • Open Access

    Aeromonas spp.: an emerging pathogen?

    by Andrea Bartolini, Giulia Zorzi, Elena Castellani, Valeria Besutti

    The aim of this study is to identify and monitor the presence of Aeromonas spp. strains in stool cultures. We analyzed 5564 stool cultures from September 2012 to August 2013. Sixty-three patients were positive for Aeromonas spp. The most frequent symptoms were: diarrhea (46.0%) and abdominal pain (12.7%). Pediatric subjects were 28. Samples’ microscopic examination showed leukocytes in 38.1% of cases. It is still controversial whether Aeromonas are responsible for human gastroenteritis, but their presence in faecies of symptomatic patients supports their etiologic role. We propose search for toxins by polymerase chain reaction to identify strains that require an antibiotic therapy.

  • Open Access

    Talking of... Dientamoeba fragilis

    by Giulia Zorzi, Ettore De Canale, Lucia Rossi, Valeria Besutti

    Introduction: Dientamoeba fragilis is a protozoan parasite of human gastrointestinal tract with worldwide distribution and a controversial pathogenic role. Data on prevalence and geographical distribution are underestimated for difficult microscopic recognition and “fragility” of the protozoan. Generally to perform the O & P exam for identification of D. fragilis it is necessary to recur to a permanent stain and to an expert microscopist. Methods: we analyzed fecal samples of 3907 patients enrolled among the patients referred to the Service of Microbiology of Padova University Hospital for routine parassitology examinations from June 2011 to June 2012. The aim of this study was to document the prevalence and the clinical features of D. fragilis infection. The laboratory detection rate of the organism is greatly enhanced by use of preservative to fix stool specimens immediately after passage. As previously described for a rapid identification of D. fragilis, in unstained fixed fecal material by direct microscopy (400X), the demonstration of the characteristic “golf-club” and “acanthopodia-like” structures are suitable. Results: in this study the prevalence was found to be 6.8%, higher than our previous reports. Out of the 267 patients in which we detected D. fragilis, 26.0% presented with extra-intestinal symptoms, 19.8% reported gastrointestinal complaints and 17.0% referred abdominal pain. Conclusions: D. fragilis, even if considered a neglected parasite, is not rare and the presence of this fecal agent is associated to various intestinal and probably systemic clinical symptoms, even though asymptomatic carriers have been reported. D. fragilis infects in high rates among close household contacts; so the Authors stress the importance of screening close contacts to prevent re-infections after treatment.